drugset
drugset / Trial / NCT06702995

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT06702995 ↗

Phase 1/2 Recruiting 307 enrolled Evopoint Biosciences Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.

Timeline

Start
2023-04-19
Primary completion
2026-05-13
Completion
2026-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject XNW5004 Unknown — Oral
Background Enzalutamide Other / unclassified 160 mg Oral

Indications

castration-resistant prostate carcinoma